Document is current

Article History

First Online: 25 July 2022

Competing interests

: J.G.: Patvocates is providing consultancy and advice on patient engagement to the following companies: Alnylam, AstraZeneca, Bayer, Boehringer-Ingelheim, Biomarin, Bristol-Myers Squibb, Daiichi Sankyo, Gilead, Janssen, Merck, Novartis, Pfizer, Roche, Servier, Sanofi, Sobi, UCB, Vifor. C.B.: During the last 3 years, C.B. has received consulting fees from Acadia pharmaceutical company, AARP, Addex pharmaceutical company, Eli Lily, Enterin pharmaceutical company, GWPharm, H.Lundbeck pharmaceutical company, Novartis pharmaceutical company, Janssen Pharmaceuticals, Johnson and Johnson pharmaceuticals, Novo Nordisk pharmaceutical company, Orion Corp pharmaceutical company, Otsuka America Pharm Inc, Sunovion Pharm. Inc, Suven pharmaceutical company, Roche pharmaceutical company, Biogen pharmaceutical compnay, Synexus clinical research organisation and TauRx pharmaceutical company. During the last 3 years C.B. has received research grants from: Synexus clinical research organisation, Roche pharmaceutical company and Novo Nordisk pharmaceutical company. He also receives an honoraium as Faculty on the Harvard Medical Schoold Dementia Cource once annually. E.I.: works for Rare Cancers Australia. C.L.: works for Reverba. G.H. and A.C. declare no competing interests.